Agitation in nursing home residents with dementia (VIDEANT trial): effects of a cluster-randomized, controlled, guideline implementation trial

J Am Med Dir Assoc. 2013 Sep;14(9):690-5. doi: 10.1016/j.jamda.2013.05.017. Epub 2013 Jul 1.

Abstract

Objective: To test the effect of a complex guideline-based intervention on agitation and psychotropic prescriptions.

Design, setting, participants: Cluster randomized controlled trial (VIDEANT) with blinded assessment of outcome in 18 nursing homes in Berlin, Germany, comprising 304 dementia patients.

Intervention: Training, support, and activity therapy intervention, delivered at the level of each nursing home, focusing on the management of agitation in dementia. Control group nursing homes received treatment as usual.

Measurements: Levels of agitated and disruptive behavior (Cohen-Mansfield agitation inventory [CMAI]) as the primary outcome. Number of neuroleptics, antidepressants, and cholinesterase inhibitors (ChEIs) prescribed in defined daily dosages (DDDs).

Results: Of 326 patients screened, 304 (93.3%) were eligible and cluster-randomized to 9 intervention (n = 163) and 9 control (n = 141) nursing homes. Data were collected from 287 (94.4%) patients at 10 months. At 10 months, compared with controls, nursing home residents with dementia in the intervention group exhibited significantly less agitation as measured with the CMAI (adjusted mean difference, 6.24; 95% CI 2.03-14.14; P = .009; Cohen's d = 0.43), received fewer neuroleptics (P < .05), more ChEIs (P < .05), and more antidepressants (P < .05).

Conclusion: Complex guideline-based interventions are effective in reducing agitated and disruptive behavior in nursing home residents with dementia. At the same time, increased prescription of ChEIs and antidepressants together with decreased neuroleptic prescription suggests an effect toward guideline-based pharmacotherapy.

Keywords: Dementia; agitation; guideline; nursing home; trial.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged, 80 and over
  • Antidepressive Agents / therapeutic use
  • Antipsychotic Agents / therapeutic use
  • Behavior Therapy
  • Cholinesterase Inhibitors / therapeutic use
  • Cluster Analysis
  • Dementia / complications*
  • Female
  • Geriatric Assessment
  • Germany
  • Humans
  • Male
  • Nursing Homes*
  • Practice Guidelines as Topic*
  • Psychomotor Agitation / drug therapy*
  • Psychomotor Agitation / etiology*
  • Psychomotor Agitation / psychology
  • Treatment Outcome

Substances

  • Antidepressive Agents
  • Antipsychotic Agents
  • Cholinesterase Inhibitors

Associated data

  • ISRCTN/ISRCTN43578978